The final 2026 order
DEA signed the final order on November 4 and filed it for public inspection November 9. The Federal Register published the order November 10 and the adjustments took effect that day. The order raises the 2026 aggregate production quotas to 31,654,915 grams for d,l-amphetamine, 37,108,041 grams for d-amphetamine for sale, 2,356,798 grams for hydromorphone, and 69,502,651 grams for methylphenidate for sale. DEA cites FDA shortage listings for mixed amphetamine salts tablets, hydromorphone injection, and methylphenidate tablets and film.1
The 2027 proposal
DEA published a separate notice on November 10 proposing 2027 aggregate quotas. Electronic comments are due by 11:59 p.m. Eastern on December 10, 2026. Written comments must be postmarked by December 10. DEA will establish the 2027 figures in a later final order.2
What to track in purchasing
Treat the higher limits as a supply signal. Confirm availability by strength, dosage form, and package with the wholesaler before changing reorder levels or giving a patient a pickup estimate. Track the products your pharmacy actually dispenses so you can tell when allocations or backorders improve.
Source notes
- Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h), 91 Fed. Reg. 72,564, 72,564–66 (Nov. 10, 2026).
- Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027, 91 Fed. Reg. 72,566, 72,566–67 (Nov. 10, 2026).